{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T02:34:00Z","timestamp":1767839640068,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"52","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["VxHO-000034"],"award-info":[{"award-number":["VxHO-000034"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.vaccine.2021.11.006","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T01:05:04Z","timestamp":1637024704000},"page":"7646-7654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain"],"prefix":"10.1016","volume":"39","author":[{"given":"Yoana","family":"Ivanova-Markova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-0961","authenticated-orcid":false,"given":"Almudena","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Garc\u00eda-Agua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio J.","family":"Garc\u00eda-Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Amanda Vallejo-Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rub\u00e9n","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"de Gomensoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria del Carmen","family":"Gonzalez-Inchausti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najida","family":"Begum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Tafalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.vaccine.2021.11.006_b0005","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.vaccine.2021.11.006_b0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/INF.0000000000001048","article-title":"The burden of pediatric invasive meningococcal disease in Spain (2008\u20132013)","volume":"35","author":"Rivero-Calle","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2021.11.006_b0015","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1016\/j.vaccine.2011.05.089","article-title":"The burden of hospitalizations for meningococcal infection in Spain (1997-2008)","volume":"29","author":"Gil-Prieto","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.11.006_b0020","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2021.11.006_b0025","unstructured":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades. Red Nacional de Vigilancia Epidemiol\u00f3gica. Instituto de Salud Carlos III. Enfermedad meningoc\u00f3cica. Vigilancia de la temporada 2017-2018. Resultados de la Red Nacional de Vigilancia Epidemiol\u00f3gica, https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/archivos%20A-Z\/Enfer_Meningoc%C3%B3cica\/RENAVE_EMI-2017-18.pdf#search=meningitis; 2018 [accessed 19 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0030","unstructured":"Consejo Interterritorial. Sistema Nacional de Salud. Calendario com\u00fan de vacunaci\u00f3n a lo largo de toda la vida. Calendario recomendado a\u00f1o 2021, https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/docs\/CalendarioVacunacion_Todalavida.pdf; 2021 [accessed 26 May 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0035","unstructured":"Direccion general de salud publica, calidad e innovacion. Ministerio de Sanidad, Consumo y Bienestar Social. Preguntas y Respuestas sobre la Vacunaci\u00f3n frente a la Meningitis, https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/docs\/Preguntas_respuestas_Vacunacion_frente_meningitis.pdf; 2019 [accessed 26 May 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0040","unstructured":"Servicion Canario de la Salud. Gobierno de Canarias. Calendario oficial de vacunaciones para todas las edades de la vida https:\/\/www3.gobiernodecanarias.org\/sanidad\/scs\/contenidoGenerico.jsp?idDocument=3cc62be0-9746-11e0-ba66-75bd8cf93e41&idCarpeta=b25ca6dc-a9a4-11dd-b574-dd4e320f085c; 2020 [accessed 26 May 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0045","unstructured":"Junta de Castilla y Leon - Consejeria de sanidad. Calendario vacunal para toda la vida de Castilla y Le\u00f3n, https:\/\/www.saludcastillayleon.es\/es\/vacunaciones\/calendario-vacunal-toda-vida-castilla-leon; 2021 [accessed 26 May 2021]"},{"issue":"10","key":"10.1016\/j.vaccine.2021.11.006_b0050","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40273-018-0679-5","article-title":"Costs of invasive meningococcal disease: a global systematic review","volume":"36","author":"Wang","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.vaccine.2021.11.006_b0055","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","article-title":"The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany","volume":"37","author":"Scholz","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.11.006_b0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jinf.2008.10.009","article-title":"Hospital admissions for meningococcal infection in Spain (1997\u20132005)","volume":"58","author":"San Roman Montero","year":"2009","journal-title":"J Infect"},{"issue":"39","key":"10.1016\/j.vaccine.2021.11.006_b0065","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1016\/j.vaccine.2014.07.019","article-title":"Costs of surviving meningococcal disease in Spain: evaluation for two cases of severe meningitis and septicaemia","volume":"32","author":"Darb\u00e0","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2021.11.006_b0070","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2165\/00019053-200624090-00005","article-title":"Cost-of-illness studies","volume":"24","author":"Akobundu","year":"2006","journal-title":"PharmacoEconomics"},{"issue":"2","key":"10.1016\/j.vaccine.2021.11.006_b0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","article-title":"Propuesta de gu\u00eda para la evaluaci\u00f3n econ\u00f3mica aplicada a las tecnolog\u00edas sanitarias","volume":"24","author":"L\u00f3pez Bastida","year":"2010","journal-title":"Gac Sanit"},{"key":"10.1016\/j.vaccine.2021.11.006_b0080","unstructured":"Instituto Nacional de Estad\u00edstica. Demografia y poblacion. Series detalladas desde 2002. Resultados Nacionales. Poblaci\u00f3n residente por fecha, sexo y edad. Datos 1 de enero de 2019, https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=9663; 2019 [accessed 20 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0085","unstructured":"Instituto Nacional de Estadistica. Esperanza de vida a distintas edades por periodo y sexo. Brecha de g\u00e9nero, https:\/\/www.ine.es\/jaxi\/Datos.htm?path=\/t00\/mujeres_hombres\/tablas_1\/l0\/&file=d01005.px#!tabs-tabla; 2018 [accessed 20 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0090","unstructured":"Instituto Nacional de Estad\u00edstica. \u00cdndice de Precios de Consumo. Base 2016. Medias anuales. \u00cdndices nacionales: general y de grupos ECOICOP, http:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=22553; 2020 [accessed 21\/04\/2021]"},{"issue":"6","key":"10.1016\/j.vaccine.2021.11.006_b0095","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40258-018-0416-4","article-title":"Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review","volume":"16","author":"Pike","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.11.006_b0100","doi-asserted-by":"crossref","first-page":"i89","DOI":"10.1136\/ard.2009.117150","article-title":"The value of productivity: human-capital versus friction-cost method","volume":"69","author":"van den Hout","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2021.11.006_b0105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/0277-9536(92)90131-9","article-title":"Towards a new approach for estimating indirect costs of disease","volume":"34","author":"Koopmanschap","year":"1992","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2021.11.006_b0110","unstructured":"Ministerio de Sanidad, Consumo y Bienestar Social. Registro de Actividad de Atenci\u00f3n Especializada - RAE-CMBD. Diagn\u00f3sticos Principales, https:\/\/pestadistico.inteligenciadegestion.mscbs.es\/PUBLICOSNS\/Comun\/Cubo.aspx?IdNodo=23611; 2017 [accessed 20 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0115","unstructured":"Ministry of Health, Consumptione and Social Welfare. Catalogue of sanitarian products included in the Spanish National Health System pharmaceutical provision, https:\/\/www.mscbs.gob.es\/profesionales\/nomenclator.do; 2021 [accessed 21 May 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0120","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta Nacional de Salud. Microdatos. Adultos y ni\u00f1os, http:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736176783&menu=resultados&secc=1254736195295&idp=1254735573175; 2017 [accessed 20 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12889-015-1693-6","article-title":"Public health management of invasive meningococcal disease in Baden-Wuerttemberg, Germany, 2012: adherence to guidance and estimation of resources required as determined in a survey of local health authorities","volume":"15","author":"Murajda","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2021.11.006_b0130","unstructured":"Imserso. Instituto de Mayores y Servicios Sociales. Beneficios e importes de la n\u00f3mina de Prestaciones Sociales y Econ\u00f3micas para personas con discapacidad a nivel nacional, https:\/\/www.imserso.es\/imserso_01\/documentacion\/estadisticas\/prestaciones_sociales_economicas_lismi\/prestaciones_sociales_economicas_lismi\/tot_nac\/index.htm; 2021 [accessed 25 May 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0135","unstructured":"Instituto Nacional de Estad\u00edstica. El Empleo de las Personas con Discapacidad. Serie 2014-2018. Prestaciones seg\u00fan sean derivadas de incapacidad por tipo de discapacidad, https:\/\/ine.es\/jaxiT3\/Tabla.htm?path=\/t22\/p320\/base_2011\/serie\/l0\/&file=09005.px; 2018 [accessed 22 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0140","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta de poblaci\u00f3n activa. Ocupados por sexo y grupo de edad. Valores absolutos y porcentajes respecto del total de cada sexo, https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=4745; 2019 [accessed 22 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0145","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta cuatrienal de estructura salarial 2018. Ganancia media anual por trabajador y sexo seg\u00fan edad, https:\/\/www.ine.es\/jaxi\/Datos.htm?path=\/t22\/p133\/a2018\/provi\/l0\/&file=02003.px#!tabs-tabla; 2018 [accessed 22 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0150","unstructured":"Instituto Nacional de Estad\u00edstica. Demograf\u00eda y poblaci\u00f3n \/Fen\u00f3menos demogr\u00e1ficos \/Indicadores demogr\u00e1ficos b\u00e1sicos \/ Datos provisionales 2019, https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736177003&menu=ultiDatos&idp=1254735573002; 2019 [accessed 22 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0155","unstructured":"Instituto Nacional de Estad\u00edstica. El Salario de las Personas con Discapacidad. Serie 2010-2018. Ganancia anual, https:\/\/www.ine.es\/jaxi\/Datos.htm?path=\/t22\/p331\/serie_anual\/l0\/&file=01011.px#!tabs-tabla; 2018 [accessed 22 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0160","unstructured":"Instituto Nacional de Estad\u00edstica. El Empleo de las Personas con Discapacidad. Serie 2014-2018. Tasas de actividad y empleo por tipo de discapacidad, https:\/\/www.ine.es\/jaxi\/Datos.htm?path=\/t22\/p320\/base_2015\/serie\/l0\/&file=03004.px#!tabs-tabla; 2018 [accessed 22 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0165","unstructured":"Blanco A, Chueca A, L\u00f3pez Ruiz JA. Madrid: Universidad Pontificia Comillas, C\u00e1tedra Jos\u00e9 Mar\u00eda Mart\u00edn Patino de la Cultura del Encuentro, https:\/\/www.comillas.edu\/es\/catedra-jose-maria-martin-patino-de-la-cultura-del-encuentro\/publicaciones; 2017 [accessed 25 June 2021]"},{"issue":"5","key":"10.1016\/j.vaccine.2021.11.006_b0170","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1157\/13092984","article-title":"Estudio de costes de la gripe [Study of flu costs]","volume":"38","author":"Badia Llach","year":"2006","journal-title":"Atenci\u00f3n Primaria"},{"issue":"23","key":"10.1016\/j.vaccine.2021.11.006_b0175","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1016\/S0264-410X(03)00264-0","article-title":"Epidemiology and economic impact of varicella in immunocompetent children in Spain: a nation-wide study","volume":"21","author":"D\u0131\u0301ez-Domingo","year":"2003","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2021.11.006_b0180","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1016\/j.vaccine.2014.04.058","article-title":"Economic and psychosocial impact of rotavirus infection in Spain: a literature review","volume":"32","author":"\u00c1lvarez Alde\u00e1n","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.11.006_b0185","unstructured":"Vallejo-Aparicio LA, Carmo M, Callejo D, P\u00e9rez A, Garc\u00eda A, Rodr\u00edguez R, et al. The relationship betweeen the income per capita level of families and the access to multicomponent meningococcal serogroup B (4CMenB) vaccination in Spain. Presented at: X Congress of the Spanish Society of Paedriatics (SEIP); March 11\u201313 2021; ID 278."},{"key":"10.1016\/j.vaccine.2021.11.006_b0190","unstructured":"Comit\u00e9 Asesor de Vacunas (CAV) de la Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda y Centro Nacional de Epidemiolog\u00eda Enfermedad meningoc\u00f3cica en Espa\u00f1a, temporada 2019-2020, https:\/\/vacunasaep.org\/profesionales\/noticias\/enfermedad-meningococica-Espana-2019-2020; 2020 [accessed 27 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0195","unstructured":"Boletin Epidemiologico Semanal. Red Nacional de Vigilancia Epidemiol\u00f3gica. Instituto de Salud Carlos III. Informe Semanal de Vigilancia N\u00b043 del a\u00f1o 2020, https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Boletines\/Documents\/Boletin_Epidemiologico_en_red\/boletines%20en%20red%202020\/IS_N%C2%BA43-201021-WEB.pdf; 2020 [accessed 26 May 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0200","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta continua de hogares, https:\/\/www.ine.es\/dyngs\/INEbase\/es\/operacion.htm?c=Estadistica_C&cid=1254736176952&menu=ultiDatos&idp=1254735572981; 2019 [accessed 20 April 2021]"},{"key":"10.1016\/j.vaccine.2021.11.006_b0205","unstructured":"Ministerio de Educaci\u00f3n y Formaci\u00f3n Profesional. Sistema estatal de indicadores de la educaci\u00f3n 2020, https:\/\/sede.educacion.gob.es\/publiventa\/descarga.action?f_codigo_agc=21166; 2020 [accessed 20 April 2021]"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21014407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:07:14Z","timestamp":1759403234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21014407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0264410X21014407"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}